Effect of Sodium-Glucose Cotransporter-2 inhibitor in patients with type 2 daibetes mellitus

Trial Profile

Effect of Sodium-Glucose Cotransporter-2 inhibitor in patients with type 2 daibetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2016 Status changed from recruiting to completed.
    • 26 Oct 2016 UMIN record has not specified the primary drug of focus for this study. But as per the results, this trial is focusing on SGLT2 inhibitor ipragliflozin. So I have retrived this discarded bundle of UMIN record and integrated results .
    • 26 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top